Hence, having a clear and consistent biomarker to objectively assess AD is important and therefore represents a clear unmet clinical need.[193, 194] Researchers have proposed several biomolecules as markers for AD, including the thymus and activation‐regulated chemokines, macrophage‐derived chemokines, e‐selectin, immunoglobulin E and several other molecules (summarized in Table 5).[136, 137, 138, 139, 140, 141]. This evidence concerns the gene SELE and Alzheimer disease.